0 10 Surfactant surfactant JJ 11 18 protein protein NN 19 20 A a NN 21 30 activates activate VBZ 31 39 NF-kappa NF-kappa NNP 40 41 B B NNP 42 44 in in IN 45 48 the the DT 49 54 THP-1 thp-1 NN 55 64 monocytic monocytic JJ 65 69 cell cell NN 70 74 line line NN 74 75 . . . 77 80 The the DT 81 91 expression expression NN 92 94 of of IN 95 99 many many JJ 100 105 genes gene NNS 106 109 for for IN 110 115 which which WDT 116 124 products product NNS 125 128 are be VBP 129 137 involved involve VBN 138 140 in in IN 141 153 inflammation inflammation NN 154 156 is be VBZ 157 167 controlled control VBN 168 170 by by IN 171 174 the the DT 175 190 transcriptional transcriptional JJ 191 200 regulator regulator NN 201 208 nuclear nuclear JJ 209 215 factor factor NN 216 217 ( ( ( 217 226 NF)-kappa NF)-kappa NNP 227 229 B. B. NNP 230 237 Because because IN 238 248 surfactant surfactant JJ 249 256 protein protein NN 257 258 ( ( ( 258 260 SP SP NNP 260 261 ) ) ) 262 263 A A NNP 264 266 is be VBZ 267 275 involved involve VBN 276 278 in in IN 279 284 local local JJ 285 289 host host NN 290 297 defense defense NN 298 300 in in IN 301 304 the the DT 305 309 lung lung NN 310 313 and and CC 314 320 alters alter VBZ 321 327 immune immune JJ 328 332 cell cell NN 333 341 function function NN 342 344 by by IN 345 355 modulating modulate VBG 356 359 the the DT 360 370 expression expression NN 371 373 of of IN 374 389 proinflammatory proinflammatory JJ 390 399 cytokines cytokine NNS 400 402 as as RB 403 407 well well RB 408 410 as as IN 411 418 surface surface NN 419 427 proteins protein NNS 428 436 involved involve VBN 437 439 in in IN 440 452 inflammation inflammation NN 452 453 , , , 454 456 we we PRP 457 469 hypothesized hypothesize VBD 470 474 that that IN 475 479 SP-A SP-A NNP 480 486 exerts exert VBZ 487 490 its its PRP$ 491 497 action action NN 497 498 , , , 499 501 at at IN 502 507 least least JJS 508 510 in in IN 511 515 part part NN 515 516 , , , 517 520 via via IN 521 531 activation activation NN 532 534 of of IN 535 543 NF-kappa NF-kappa NNP 544 546 B. B. NNP 547 549 We we PRP 550 554 used use VBD 555 558 gel gel NN 559 564 shift shift NN 565 571 assays assay NNS 572 574 to to TO 575 584 determine determine VB 585 592 whether whether IN 593 597 SP-A SP-A NNP 598 607 activated activate VBD 608 616 NF-kappa NF-kappa NNP 617 618 B B NNP 619 621 in in IN 622 625 the the DT 626 631 THP-1 thp-1 NN 632 636 cell cell NN 637 641 line line NN 641 642 , , , 643 644 a a DT 645 650 human human JJ 651 660 monocytic monocytic JJ 661 665 cell cell NN 666 670 line line NN 670 671 . . . 672 682 Activation Activation NNP 683 685 of of IN 686 694 NF-kappa NF-kappa NNP 695 696 B B NNP 697 699 in in IN 700 705 THP-1 thp-1 NN 706 711 cells cell NNS 712 714 by by IN 715 719 SP-A SP-A NNP 720 725 doses dose NNS 726 728 as as RB 729 732 low low JJ 733 735 as as IN 736 737 1 1 CD 738 750 microgram/ml microgram/ml NN 751 759 occurred occur VBD 760 766 within within IN 767 769 30 30 CD 770 773 min min NN 774 776 of of IN 777 781 SP-A SP-A NNP 782 791 treatment treatment NN 791 792 , , , 793 799 peaked peak VBD 800 802 at at IN 803 805 60 60 CD 806 809 min min NN 809 810 , , , 811 814 and and CC 815 819 then then RB 820 828 declined decline VBD 828 829 . . . 830 834 This this DT 835 845 activation activation NN 846 848 is be VBZ 849 858 inhibited inhibit VBN 859 861 by by IN 862 867 known known JJ 868 878 inhibitors inhibitor NNS 879 881 of of IN 882 890 NF-kappa NF-kappa NNP 891 892 B B NNP 893 895 or or CC 896 898 by by IN 899 911 simultaneous simultaneous JJ 912 921 treatment treatment NN 922 924 of of IN 925 928 the the DT 929 934 cells cell NNS 935 939 with with IN 940 950 surfactant surfactant JJ 951 957 lipids lipid NNS 957 958 . . . 959 967 Moreover moreover RB 967 968 , , , 969 972 the the DT 973 981 NF-kappa NF-kappa NNP 982 983 B B NNP 984 994 inhibitors inhibitor NNS 995 1002 blocked block VBD 1003 1017 SP-A-dependent sp-a-dependent JJ 1018 1027 increases increase NNS 1028 1030 in in IN 1031 1036 tumor tumor NN 1037 1045 necrosis necrosis NN 1046 1058 factor-alpha factor-alpha NN 1059 1063 mRNA mrna NN 1064 1070 levels level NNS 1070 1071 . . . 1072 1077 These these DT 1078 1090 observations observation NNS 1091 1098 suggest suggest VBP 1099 1100 a a DT 1101 1110 mechanism mechanism NN 1111 1113 by by IN 1114 1119 which which WDT 1120 1124 SP-A SP-A NNP 1125 1130 plays play VBZ 1131 1132 a a DT 1133 1137 role role NN 1138 1140 in in IN 1141 1144 the the DT 1145 1157 pathogenesis pathogenesis NN 1158 1160 of of IN 1161 1165 some some DT 1166 1170 lung lung NN 1171 1181 conditions condition NNS 1182 1185 and and CC 1186 1191 point point VBP 1192 1194 to to TO 1195 1204 potential potential JJ 1205 1216 therapeutic therapeutic JJ 1217 1225 measures measure NNS 1226 1230 that that WDT 1231 1236 could could MD 1237 1239 be be VB 1240 1244 used use VBN 1245 1247 to to TO 1248 1255 prevent prevent VB 1256 1260 SP-A SP-A NNP 1261 1268 induced induced JJ 1269 1281 inflammation inflammation NN 1282 1284 in in IN 1285 1288 the the DT 1289 1293 lung lung NN 1293 1294 . . .